Why IBD Patients Should Know About Biosimilars Last month, the FDA approved the first biosimilar product for Crohn’s disease and ulcerative colitis. A biosimilar is a “similar” copy to another biologic therapy, however, they are not identical and therefore are not generic versions. While this approved treatment is not yet available in the U.S. market, it is important for IBD patients and caregivers to learn what a biosimilar is and how they differ from other biologic therapies.
Members of CCFA’s Government & Industry Affairs Committee will present an educational webinar on June 1st, from 8-9 PM ET to introduce this newly approved treatment and answer questions. This is the first of several other educational pieces that CCFA will offer on biosimilars.
Wednesday, June 1st, 2016
8 PM -9 PM ET
Speakers: David T. Rubin, MD and Noa Krugliak Cleveland, MD – University of Chicago Medicine
Latest Crohn’s & Colitis Foundation of America-Medscape Activity Provides Tips for Patients and Care Partners on Managing Short Bowel Syndrome
“Managing Short Bowel Syndrome: Tips for Patients and Care Partners” is a new online education activity designed to help patients and their caregivers learn about short bowel syndrome, management options, dietary concerns, and possible adverse effects from treatment.
These modules are developed through a partnership between the Crohn’s & Colitis Foundation of America and Medscape Education, and supported by an independent educational grant from NPS Pharmaceuticals, an indirect subsidiary of Shire North America Group.
View the patient education activity on Managing Short Bowel Syndrome: Tips for Patients and Caregivers today.